
Novo Nordisk and five other pharmaceutical companies have sued the US government – they argue the US discount system is poorly implemented in several US hospitals, driving uppatient costs.
The US Health Resources and Services Administration (HRSA) now responds by threatening a fine of USD 5,000 (DKK 31,741) per violation of the discount program in question, Danish business daily Børsen reports.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Fruergaard leveraging experience from Danish partnerships in key roles in Brussels
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.